-
Je něco špatně v tomto záznamu ?
Neuroprotective efficacy of newly developed oximes in comparison with currently available oximes in tabun-poisoned rats
Jiri Kassa, Jan Misik, Jana Zdarova Karasova
Jazyk angličtina Země Česko
Typ dokumentu práce podpořená grantem
- MeSH
- antidota MeSH
- atropin aplikace a dávkování terapeutické užití MeSH
- chemické bojové látky * toxicita MeSH
- cholinesterasové inhibitory * MeSH
- krysa rodu rattus MeSH
- neuroprotektivní látky MeSH
- neurotoxické syndromy farmakoterapie MeSH
- neurotoxiny MeSH
- nitrily MeSH
- organofosfáty MeSH
- organofosforové sloučeniny * toxicita MeSH
- oximy * aplikace a dávkování farmakokinetika terapeutické užití MeSH
- trimedoxim * aplikace a dávkování terapeutické užití MeSH
- zvířata MeSH
- Check Tag
- krysa rodu rattus MeSH
- zvířata MeSH
- Publikační typ
- práce podpořená grantem MeSH
The ability of two newly developed oximes (K361, K378) to reduce tabun-induced acute neurotoxic signs and symptoms was compared with the oxime K203 and trimedoxime using a functional observational battery. The neuroprotective effects of the oximes studied combined with atropine on rats poisoned with tabun at a sublethal dose (310 μg/kg i.m.; 90% of LD50 value) were evaluated. Tabun-induced neurotoxicity was monitored by functional observational battery at 2 h following tabun challenge. The results indicate that all tested oximes combined with atropine enable tabun-poisoned rats to survive till the end of experiment. Both newly developed oximes (K361, K378) combined with atropine were able to decrease tabun-induced neurotoxicity in the case of sublethal poisonings although they did not eliminate all tabun-induced acute neurotoxic signs and symptoms. Their ability to decrease tabun-induced acute neurotoxicity was slightly lower than that of trimedoxime and the oxime K203. Therefore, the newly developed oximes are not suitable for the replacement of commonly used oximes (especially trimedoxime and obidoxime) in the treatment of acute tabun poisonings.
Literatura
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15021871
- 003
- CZ-PrNML
- 005
- 20150902150925.0
- 007
- ta
- 008
- 150626s2015 xr a f 000 0|eng||
- 009
- AR
- 024 7_
- $2 doi $a 10.1016/j.jab.2014.10.001
- 040 __
- $a ABA008 $d ABA008 $e AACR2 $b cze
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Kassa, Jiří, $d 1956- $7 mzk2003181395 $u Department of Toxicology and Military Pharmacy, Faculty of Military Health Science, University of Defense, Hradec Králové
- 245 10
- $a Neuroprotective efficacy of newly developed oximes in comparison with currently available oximes in tabun-poisoned rats / $c Jiri Kassa, Jan Misik, Jana Zdarova Karasova
- 504 __
- $a Literatura
- 520 3_
- $a The ability of two newly developed oximes (K361, K378) to reduce tabun-induced acute neurotoxic signs and symptoms was compared with the oxime K203 and trimedoxime using a functional observational battery. The neuroprotective effects of the oximes studied combined with atropine on rats poisoned with tabun at a sublethal dose (310 μg/kg i.m.; 90% of LD50 value) were evaluated. Tabun-induced neurotoxicity was monitored by functional observational battery at 2 h following tabun challenge. The results indicate that all tested oximes combined with atropine enable tabun-poisoned rats to survive till the end of experiment. Both newly developed oximes (K361, K378) combined with atropine were able to decrease tabun-induced neurotoxicity in the case of sublethal poisonings although they did not eliminate all tabun-induced acute neurotoxic signs and symptoms. Their ability to decrease tabun-induced acute neurotoxicity was slightly lower than that of trimedoxime and the oxime K203. Therefore, the newly developed oximes are not suitable for the replacement of commonly used oximes (especially trimedoxime and obidoxime) in the treatment of acute tabun poisonings.
- 650 12
- $a chemické bojové látky $x toxicita $7 D002619
- 650 12
- $a cholinesterasové inhibitory $7 D002800
- 650 12
- $a organofosforové sloučeniny $x toxicita $7 D009943
- 650 _2
- $a organofosfáty $7 D010755
- 650 _2
- $a nitrily $7 D009570
- 650 _2
- $a neurotoxiny $7 D009498
- 650 _2
- $a neurotoxické syndromy $x farmakoterapie $7 D020258
- 650 12
- $a oximy $x aplikace a dávkování $x farmakokinetika $x terapeutické užití $7 D010091
- 650 12
- $a trimedoxim $x aplikace a dávkování $x terapeutické užití $7 D014289
- 650 _2
- $a atropin $x aplikace a dávkování $x terapeutické užití $7 D001285
- 650 _2
- $a neuroprotektivní látky $7 D018696
- 650 _2
- $a antidota $7 D000931
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a zvířata $7 D000818
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Misik, Jan $u Department of Toxicology and Military Pharmacy, Faculty of Military Health Science, University of Defense, Hradec Králové
- 700 1_
- $a Žďárová Karasová, Jana, $d 1982- $7 xx0099787 $u Department of Toxicology and Military Pharmacy, Faculty of Military Health Science, University of Defense, Hradec Králové
- 773 0_
- $t Journal of applied biomedicine $x 1214-021X $g Roč. 13, č. 1 (2015), s. 39-46 $w MED00012667
- 856 41
- $u https://jab.zsf.jcu.cz/pdfs/jab/2015/01/06.pdf $y plný text volně přístupný
- 910 __
- $a ABA008 $b B 2301 $c 1249 $y 4 $z 0
- 990 __
- $a 20150626071913 $b ABA008
- 991 __
- $a 20150902151045 $b ABA008
- 999 __
- $a ok $b bmc $g 1082269 $s 904839
- BAS __
- $a 3
- BMC __
- $a 2015 $b 13 $c 1 $d 39-46 $i 1214-021X $m Journal of Applied Biomedicine $x MED00012667
- LZP __
- $c NLK137 $d 20150902 $a NLK 2015-31/vt